On May 6, 2025, Avadel Pharmaceuticals announced a favorable ruling from the U.S. Court of Appeals, allowing them to seek FDA approval for LUMRYZ for uses beyond narcolepsy, after overturning parts of a prior injunction from a Delaware court.